Today, our Western Europe business is primarily generics while the Central Eastern Europe business is driven by branded formulations. Our commercial operations in Western Europe are built on three revenue streams – Product distribution, Dossier licensing and supply of finished dosage to other players. Our diverse portfolio reflects a healthy mix of oral solids and semi-solid products that are focused in niche therapeutic segments. Our focus therapeutic areas include Dermatology, Respiratory, Oncology and Cardiology. We have a strong presence in UK, Germany as well as the Netherlands and are expanding our reach across other key markets such as Spain, Denmark, Sweden and Ireland. We are recognized as the fastest growing generics company in Germany. In the Central and Eastern European markets, we have a portfolio of more than 100 products. We focus on CNS, Respiratory, Cardiovascular and Metabolic therapeutic segments. Poland, Czech Republic, Slovakia and Romania are key markets in this region.

Glenmark recently entered into a Strategic Development & Licensing Agreement with Celon Pharma S.A. to develop and market a generic version of GlaxoSmithKline’s Seretide Accuhaler® product – Fluticasone /Salmeterol dry powder Inhaler in Europe. Glenmark has Semi-exclusive Marketing & Distribution rights of the product across 15 European countries including Great Britain, Germany, Belgium, the Netherlands, Italy, Sweden, Norway and Romania among others. This deal reinforces our growing capabilities in the respiratory segment and is a significant step towards building a strong respiratory franchise in Europe.